These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 35089116)

  • 21. [CAR-T therapy for autoimmune diseases].
    Alcaraz-Serna A; Porret R; Trueb L; Ribi C; Seebach J; Muller YD
    Rev Med Suisse; 2024 Apr; 20(868):688-693. PubMed ID: 38568061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advancements and challenges in CAR T cell therapy in autoimmune diseases.
    Schett G; Müller F; Taubmann J; Mackensen A; Wang W; Furie RA; Gold R; Haghikia A; Merkel PA; Caricchio R; D'Agostino MA; Locatelli F; June CH; Mougiakakos D
    Nat Rev Rheumatol; 2024 Sep; 20(9):531-544. PubMed ID: 39107407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CAR T cells for treating autoimmune diseases.
    Blache U; Tretbar S; Koehl U; Mougiakakos D; Fricke S
    RMD Open; 2023 Nov; 9(4):. PubMed ID: 37996128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Future of CAR T Therapeutics to Treat Autoimmune Disorders.
    Pecher AC; Hensen L; Lengerke C; Henes J
    Mol Diagn Ther; 2024 Sep; 28(5):593-600. PubMed ID: 39078456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [CAR T-cell therapy in rheumatology-What we know so far?].
    Hagen M; Wirsching A; Bohr D; Taubmann J; Müller F; Mackensen A; Grieshaber-Bouyer R; Schett G
    Z Rheumatol; 2024 Aug; 83(6):485-491. PubMed ID: 38780637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
    Boyiadzis MM; Dhodapkar MV; Brentjens RJ; Kochenderfer JN; Neelapu SS; Maus MV; Porter DL; Maloney DG; Grupp SA; Mackall CL; June CH; Bishop MR
    J Immunother Cancer; 2018 Dec; 6(1):137. PubMed ID: 30514386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
    Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
    J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance.
    Zhang Q; Lu W; Liang CL; Chen Y; Liu H; Qiu F; Dai Z
    Front Immunol; 2018; 9():2359. PubMed ID: 30369931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in off-the-shelf CAR T-cell therapy.
    Benjamin R
    Clin Adv Hematol Oncol; 2019 Mar; 17(3):155-157. PubMed ID: 30969953
    [No Abstract]   [Full Text] [Related]  

  • 31. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimeric antigen receptors: "CARs" in the fast lane for rheumatology.
    Johnson NM; Koumpouras F
    Curr Opin Rheumatol; 2024 May; 36(3):176-183. PubMed ID: 38517338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A review of chimeric antigen receptor T-cells in lymphoma.
    Anderson JK; Mehta A
    Expert Rev Hematol; 2019 Jul; 12(7):551-561. PubMed ID: 31177852
    [No Abstract]   [Full Text] [Related]  

  • 34. CAR T cell therapy for refractory pediatric systemic lupus erythematosus: a new era of hope?
    Stojkic I; Harper L; Coss S; Kallash M; Driest K; Lamb M; Ardoin SP; Akoghlanian S
    Pediatr Rheumatol Online J; 2024 Aug; 22(1):72. PubMed ID: 39118067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance.
    Chandran SS; Klebanoff CA
    Immunol Rev; 2019 Jul; 290(1):127-147. PubMed ID: 31355495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.
    Yu S; Yi M; Qin S; Wu K
    Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chimeric antigen receptor T-cell therapy beyond cancer: current practice and future prospects.
    Zhang PF; Xie D; Li Q
    Immunotherapy; 2020 Sep; 12(13):1021-1034. PubMed ID: 32727249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CAR T-cell therapy: Full speed ahead.
    Sermer D; Brentjens R
    Hematol Oncol; 2019 Jun; 37 Suppl 1():95-100. PubMed ID: 31187533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CAR-T cells: the Chinese experience.
    Wang L; Tan Su Yin E; Zhao H; Ni F; Hu Y; Huang H
    Expert Opin Biol Ther; 2020 Nov; 20(11):1293-1308. PubMed ID: 32605454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.